Cellecta, Inc. Expands Immune Profiling Portfolio with DriverMap™ Single-Cell AIR Kits for Affordable, High-Resolution Chain-Pairing of T-Cell and B-Cell Receptors

Eight kit options provide full-length, paired receptor chain data for human, mouse, or hybrid samples, without the need for specialized instruments or expensive reagents.

MOUNTAIN VIEW, Calif., July 10, 2025 /PRNewswire/ -- Cellecta, Inc., a leader in functional genomics and immune profiling technologies, today announced the launch of its new DriverMap™ Single-Cell Adaptive Immune Receptor (scAIR) TCR-BCR assay product line, a groundbreaking solution for delivering chain-pairing information from full-length T-cell and B-cell receptor chains, without the need for specialized instrumentation or complex workflows.

The DriverMap scAIR product line includes eight separate kits. Each kit delivers chain-pairing information from T-cell receptor (TCR) or B-cell receptor (BCR) profiling of human, mouse, or hybrid human-mouse samples. Two specialized human scAIR profiling kits also provide immunophenotyping data based on the expression of well-characterized T-cell or B-cell marker genes.

These novel scAIR assays enable characterization of full-length TCR α/β and BCR heavy/light chain sequences, which is useful for a variety of applications, including biomarker, epitope, immunotherapy, and neo-antigen discovery. The assays employ a straightforward multiplex PCR-based procedure with indexed primers that are used to identify TCR α/β and BCR heavy/light chain pairs from individual flow-sorted cells, or to provide chain-pair sequences for the more prevalent receptors from populations of thousands of cells.

"By eliminating the need for specialized equipment and greatly reducing per-sample costs, these scAIR kits open the door for a broader range of scientists to investigate immune clonality and cell function at single-cell resolution," said Alex Chenchik, Ph.D., president and chief scientific officer of Cellecta, Inc. "We're enabling researchers to ask—and answer—important biological questions that were previously out of reach due to technical or budgetary constraints."

Optimized for use on Illumina next-generation sequencing (NGS) platforms, the DriverMap scAIR kits integrate seamlessly into standard laboratory workflows. These kits generate NGS-ready libraries containing Cellecta's proprietary validator barcodes, which allow for quantitation without relying on droplet microfluidics or partition-based barcoding protocols.

Unlike other high-throughput TCR- or BCR-Seq systems that require upfront hardware investment, the DriverMap scAIR Kits are cost-effective and straightforward to use. Ideal for researchers who may be considering TCR- or BCR-seq to further characterize known cell populations or uncover new insights from rare cell subsets, these kits are especially useful for

• Studying rare or limited immune samples
• Profiling sorted or antigen-specific T and B cell populations
• Unlocking new research directions in immune monitoring, antibody development, and TCR-based therapies

Analysis of the DriverMap scAIR kit data is carried out with the widely used MiXCR analysis pipeline and the Platforma user interface (MiLaboratories Inc.), which supports V(D)J annotation, clonotype clustering, chain pairing analyses, and more.

The DriverMap scAIR TCR-BCR assays are the latest addition to an extensive DriverMap AIR product and service offering, which also includes bulk AIR DNA and RNA kits and services, spike-in standards, and downstream bioinformatics analysis. More information on the scAIR assays is available at cellecta.com/scAIR-kits

About Cellecta, Inc.

Cellecta, Inc. is a trusted supplier of genomic products and services that advance researchers' drug target and biomarker discovery efforts. Since 2006, we have collaborated with the world's leading pharma, biotech, government, and academic institutions. We apply our extensive expertise in immune and transcriptome profiling, functional genomics, cell engineering, and viral vector production to provide products and services that power meaningful discoveries.

For more information, visit www.cellecta.com

Cellecta, Inc.
Paul Diehl, 650-938-4050
[email protected]

or

Media:

Ruth Mercado, 650-938-4080
[email protected]

SOURCE Cellecta Inc.